BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Shows Promising Breast Cancer Data at ASCO 2025

June 2, 2025

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor BeOne Medicines Ltd. , a global oncology company, announced new

Categories

Tag: BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Shows Promising Breast Cancer Data at ASCO 2025

Share With

Recent Posts

Tracer, QIAGEN Partner on Blood-Based MRD Test for Tumors

NextGen Healthcare Adds MDP as Investor, Plans Leadership Shift

JCR Pharma Launches Unique Global Site for 50th Anniversary

3 New Members Join Southern Nevada’s Top Regional Board

MedCore Opens New GI Surgery Center & Clinic in Arkansas

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands